Brad Loncar
#Biotech investor, index provider, entrepreneur, creator of two Nasdaq-listed exchange traded funds, KC native, @univmiami hurricane.🧬🙌
Last synced from Twitter 126d ago
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS
Third-Quarter 2020 Revenues of $12.1 Billion; Reported Diluted EPS (1) of $0.39, Adjusted Diluted EPS (2) of $0.72 4% Operational Growth from Biopharma, Primarily Driven by the Ongoing Strong Performance of Vyndaqel/Vyndamax, Growth from our Leading...
Brad Loncar
$PFE - I don't see any interesting news in here on first glance.
128d
Healthcare Earnings for the Week of May 6
Brad Loncar
Earnings for the week ahead. All eyes on Pfizer tomorrow morning.
T: $LLY $MRK $NVS $PFE
W: $AMGN $GILD $GSK
T: $ILMN $MRNA $VRTX
F: $ABBV $NVO
Full schedule: loncarblog.com/october-26-202… pic.twitter.com/G5GL8OmL6U
129d
Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase
Initial hesitation by senior executives about joining the global effort puts the company in an unusual spot: behind.
Brad Loncar
This is great background on how $MRK got off to a slow start in the vaccine race by @GZuckerman.
131d
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) | Moderna, Inc.
Moderna to make statement at today’s FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting Moderna thanks PPD, its CRO partner, for the successful execution of COVE Study enrollment CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct....
Bo Cumbo jumps from the top commercial post at Sarepta to the helm of a gene therapy startup with some influential backers, big plans and $107M
After a 7-year stretch building the commercial team at Sarepta, longtime drug salesman Bo Cumbo is jumping to the entrepreneurial side of the business, taking the helm of a startup that’s got several deep-pocket investors. And he’s not just bringing...
How Pfizer Partner BioNTech Became a Leader in Coronavirus Vaccine Race
German biotech BioNTech SE worked on cancer treatments, and was developing an influenza vaccine with Pfizer Inc., when its founder, Ugur Sahin, led the company’s pivot to the coronavirus in January.
CRL spikes $1.6 billion WuXi merger over shareholder concerns - MassDevice
Charles River Laboratories International Inc. (NYSE:CRL) will leave WuXi PharmaTech (Cayman) Inc. (NYSE:WX) at the altar and take its $1.6 billion dowry with it, after failing to convince shareholders that the union was in the best interest of the...
Bringing their genetically modified gamma delta T cells to Nasdaq, IN8bio files for $86M IPO
The biotech IPO parade continues marching forward as 2020 turns toward the fourth quarter. IN8bio, a New York-based company focused on genetically modified gamma delta T cell therapies, filed to go public Friday seeking an $86 million raise. The...
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China | ImmunoGen, Inc.
The Investor Relations website contains information about ImmunoGen, Inc.'s business for stockholders, potential investors, and financial analysts.
Brad Loncar
The upfronts on China deals continue to grow. $40M to $IMGN today for its ADC mirvetuximab. This would have been unheard of a couple of years ago.
135d
Vaccine company Vaxart faces federal investigation for allegedly exaggerating role in Operation Warp Speed
Vaxart, a biotech working on a COVID-19 vaccine, is being investigated by the government and sued by investors for exaggerating its role in Operation Warp Speed.
Christie’s COVID-19 treatment raises fairness, safety questions
Former New Jersey Gov. Chris Christie’s treatment for COVID-19 raises questions about the fairness of decisions to grant access to investigational therapies, as well as the safety of exposing
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
- Updated adagrasib (MRTX849) clinical data in non-small cell lung cancer (NSCLC) patients will be featured in a plenary session at ENA - Updated adagrasib clinical data in colorectal cancer (CRC) and other KRAS G12C positive solid tumors outside of...
Brad Loncar
Maybe this was already known/assumed, but Mirati's lung cancer data got a plenary at the Triple Meeting. Oct 25th.
139d
Subscribe to read | Financial Times
News, analysis and comment from the Financial Times, the worldʼs leading global business publication
Selling stock at a clip, top Moderna doctor gets $1 million richer each week
Chief Medical Officer Tal Zaks has been selling his stock every Tuesday lately, earning him more than $50 million since the pandemic started.
Brad Loncar
One pet peeve here is that critics quoted in these stories never offer a palatable alternative. “I would be ok if they sold stock at _______ (this time).” The reality is that no scenario of executives making money would ever make them happy.
142d
COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials
Brad Loncar
$AZN says its antibody combo has been engineered to last 6 to 12 months. Entering P3 shortly.
145d
Innovate Next
An experience like no other. Innovate Next is an interactive gathering envisioned to deliver revolutionary thinking from influential leaders at the intersection of healthcare and technology. Trailblazing change-makers from some of the world’s most...
1
Brad Loncar
On January 7th, @SVB_Financial is launching Innovate Next, a virtual conference on healthcare and tech. I'm excited about what @katherun is putting together and glad to be helping in a small way. #SVBHealthcare Register here: events.svb.com/innovatenext pic.twitter.com/tiaU9tTrVG
146d
Regeneron Asks F.D.A. for Emergency Approval for Drug That Trump Claimed Cured Him
The company said that doses of the unproven treatment would be available for 50,000 patients. It’s impossible to know whether it helped the president.
Innovate Next | 1/7/21
Innovate Next is an interactive virtual global gathering envisioned to deliver revolutionary thinking from influential leaders at the intersection of healthc...
Subscribe to read | Financial Times
News, analysis and comment from the Financial Times, the worldʼs leading global business publication